Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
|
CN |
|
Clearfield Inc
NASDAQ:CLFD
|
US |
|
Establishment Labs Holdings Inc
NASDAQ:ESTA
|
CR |
|
Golden Ocean Group Ltd
NASDAQ:GOGL
|
BM |
|
Mora Telematika Indonesia Tbk PT
IDX:MORA
|
ID |
|
Superloop Ltd
ASX:SLC
|
AU |
|
Indian Overseas Bank
NSE:IOB
|
IN |
Wall Street
Price Targets
Price Targets Summary
Zhejiang Huahai Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Zhejiang Huahai Pharmaceutical Co Ltd
is 18.02 CNY
with a low forecast of 13.13 CNY and a high forecast of 23.1 CNY.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Zhejiang Huahai Pharmaceutical Co Ltd's stock price target?
Price Target
18.02
CNY
According to Wall Street analysts, the average 1-year price target for
Zhejiang Huahai Pharmaceutical Co Ltd
is 18.02 CNY
with a low forecast of 13.13 CNY and a high forecast of 23.1 CNY.
What is Zhejiang Huahai Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
6%
For the last 13 years the
compound annual growth rate for
Zhejiang Huahai Pharmaceutical Co Ltd's revenue is
14%.
The projected
CAGR
for the next 4 years is
6%.
What is Zhejiang Huahai Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
15%
For the last 13 years the
compound annual growth rate for
Zhejiang Huahai Pharmaceutical Co Ltd's operating income is
13%.
The projected
CAGR
for the next 4 years is
15%.
What is Zhejiang Huahai Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
7%
For the last 13 years the
compound annual growth rate for
Zhejiang Huahai Pharmaceutical Co Ltd's net income is
13%.
The projected
CAGR
for the next 3 years is
7%.
